Sepragen signs Infors as a distributor for its products in the UK

March 2009, Hayward, CA ... Sepragen signed a distribution agreement for its products with Infors-HT for the UK market. Infors-HT has been a distributor for its parent company based in Switzerland that provides shakers and fermentation products and instrumentation for cell culture to research institutes and biotechnology companies. “We are excited about working with Sepragen to bring innovative technologies for chromatography, scale up and bio-processing to our customers. Sepragen has been the inventors of Radial Flow Chromatography and Quantasep systems and are now introducing the single use Express bioreactors. We are proud to offer these advanced products to our customers in the UK market to both new and established Sepragen customers”, said Mr. Nick Musgrove of Infors-HT. “We have a full range of on-site service capabilities ranging from installation, training, IQ/OQ and preventative maintenance and provide our customers excellent response”, he added. Vinit Saxena, Sepragen’s CEO said that he was impressed by Infors’ commitment to its customers and expected to support Infors in bringing continued innovation to their customers.

Sepragen currently provides innovative bio-processing products that enable biotech companies to develop and produce biopharmaceuticals quickly and cost-effectively. Sepragen products are used world-wide by leading biotech companies to manufacture over twenty FDA approved drugs

Return to News and Events main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.